This study demonstrates the feasibility of using UCNPs as a promisingcandidate for high contrast breast cancer tissue labeling and brings upthe potential for quantification of HER2 expression as opposed to standardDAB labeling. The gene discussed is ERBB2; the disease is breast carcinoma.